There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report), Medtronic (MDT – Research Report) and Caribou Biosciences (CRBU – Research Report) with bullish sentiments.
Vertex Pharmaceuticals (VRTX)
Barclays analyst Gena Wang maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $472.00. The company’s shares closed last Tuesday at $412.45.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $435.60, representing a 5.5% upside. In a report issued on March 1, Goldman Sachs also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Medtronic (MDT)
In a report released yesterday, Matt Miksic from Barclays maintained a Buy rating on Medtronic, with a price target of $104.00. The company’s shares closed last Tuesday at $85.74.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $93.20, which is a 9.5% upside from current levels. In a report issued on February 29, Wells Fargo also maintained a Buy rating on the stock with a $102.00 price target.
Caribou Biosciences (CRBU)
In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Caribou Biosciences, with a price target of $30.00. The company’s shares closed last Tuesday at $5.02.
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $23.17, a 223.6% upside from current levels. In a report issued on March 11, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRTX:
- William Blair biotech analysts to hold an analyst/industry conference call
- Vertex Pharmaceuticals participates in a conference call with JPMorgan
- Vertex Pharmaceuticals downgraded to Buy from Conviction Buy at Goldman Sachs
- Vertex Pharmaceuticals CSO Altshuler sells 3,002 common shares
- Vertex Pharmaceuticals reports CHMP opinion for label extension of Kalydeco
